Germany's Merck Acquires Silence Therapeutics for $1.3 Billion

• Germany's Merck KGaA has acquired UK biotech Silence Therapeutics for $1.3 billion.
• The acquisition focuses on Silence Therapeutics' RNA drug technology.
• Silence Therapeutics' stock surged 125% following the acquisition announcement.
• The deal represents a 130% premium for Merck KGaA.
• The acquisition is expected to enhance Merck's RNA drug development capabilities.